Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
US-2024376471-A1 · Nov 14, 2024 · US
Antisense modulation of superoxide dismutase 1, soluble expression
US8993529B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993529-B2 |
| Application number | US-98792911-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 10, 2011 |
| Priority date | Jun 21, 2001 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising an antisense oligonucleotide 8 to 50 nucleobases in length targeted to the 3′ untranslated region (UTR) of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO: 3); wherein said oligonucleotide specifically hybridizes with and inhibits the expression of human superoxide dismutase 1, soluble (SEQ ID NO: 3) by at least 50%; and wherein said oligonucleotide comprises at least one modified inter…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Cross-Sectional Technologies · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993529B2 cover?
- Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of d…
- Who is the assignee on this patent?
- Bennett C Frank, Dobie Kenneth W, Isis Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1137. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).